{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:50:13Z","timestamp":1790455813282,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008459","name":"University of Calgary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bneo.2024.100050","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T12:03:15Z","timestamp":1729771395000},"page":"100050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enitociclib, a selective CDK9 inhibitor: in\u00a0vitro and in\u00a0vivo preclinical studies in multiple myeloma"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-7292","authenticated-orcid":false,"given":"Son","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3138-1953","authenticated-orcid":false,"given":"Patrick","family":"Sipila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8525-4239","authenticated-orcid":false,"given":"Melanie M.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Stelte-Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0306-4646","authenticated-orcid":false,"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Birkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-2597","authenticated-orcid":false,"given":"Raquel","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-477X","authenticated-orcid":false,"given":"Aru","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bneo.2024.100050_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bneo.2024.100050_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100050_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bneo.2024.100050_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","article-title":"The multiple mechanism of MCL1 in the regulation of cell fate","volume":"4","author":"Widden","year":"2021","journal-title":"Commun Biol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100050_bib5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy","volume":"28","author":"Diamond","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bneo.2024.100050_bib6","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/2767-9764.CRC-23-0219","article-title":"Enitociclib, a selective CDK9 inhibitor, induces complete regression of MYC+ lymphoma by downregulation of RNA polymerase II mediated transcription","volume":"3","author":"Frigault","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"W1","key":"10.1016\/j.bneo.2024.100050_bib7","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.bneo.2024.100050_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"VIP152 is a selective CDK9 inhibitor with pre-clinical in\u00a0vitro and in\u00a0vivo efficacy in chronic lymphocytic leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2024.100050_bib9","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2011.e21","article-title":"Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients","volume":"55","author":"Tsirakis","year":"2011","journal-title":"Eur J Histochem"},{"issue":"3","key":"10.1016\/j.bneo.2024.100050_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (VelcadeTM) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.bneo.2024.100050_bib11","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100050_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"10.1016\/j.bneo.2024.100050_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Chanan-Khan","year":"2013","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.bneo.2024.100050_bib14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2024.100050_bib15","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"Ten Hacken","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.bneo.2024.100050_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bneo.2024.100050_bib17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41375-022-01553-w","article-title":"Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2024.100050_bib18","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/MCB.01266-09","article-title":"Ubiquitin-independent degradation of antiapoptotic MCL-1","volume":"30","author":"Steward","year":"2010","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100050_bib19","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/MCB.20.7.2423-2435.2000","article-title":"c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt\u2019s lymphoma cells","volume":"20","author":"Gregory","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"15","key":"10.1016\/j.bneo.2024.100050_bib20","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer","volume":"64","author":"Lucking","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.bneo.2024.100050_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bneo.2024.100050_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12185-020-03005-6","article-title":"Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents","volume":"113","author":"Sato","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bneo.2024.100050_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bneo.2024.100050_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:58:00Z","timestamp":1762657080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2950328024000505"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100050","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enitociclib, a selective CDK9 inhibitor: in\u00a0vitro and in\u00a0vivo preclinical studies in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100050"}}